Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: J Comp Neurol. 2024 Mar;532(3):e25596. doi: 10.1002/cne.25596

Table 2.

CMAP Amplitude, Duration and Area

CMAP Amplitude (mV) CMAP Duration (ms) CMAP Area (mVms)
Nerve Level LPN Affected Group Control Group P value LPN Affected Group Control Group P value LPN Affected Group Control Group P value
Sciatic Proximal (Hip) 1.60 ± 1.33 (n=9) 5.56 ± 4.22 (n=8) P=0.13 9.34 ± 3.52 (n=9) 8.05 ± 2.65 (n=8) P=0.63 2.54 ± 1.78 (n=9) 8.61 ± 6.65 (n=8) P=0.09
Mid (Stifle) 1.40 ± 0.89 (n=8) 6.35 ± 3.61 (n=8) P<0.05 8.50 ± 2.84 (n=8) 7.49 ± 1.06 (n=8) P=0.77 3.12 ± 2.76 (n=8) 11.20 ± 7.43 (n=8) P<0.05
Distal (Hock) 2.05 ± 1.20 (n=9) 10.99 ± 8.03 (n=8) P<0.001 7.02 ± 2.32 (n=9) 6.52 ± 0.72 (n=8) P=0.96 3.20 ± 2.39 (n=9) 14.20 ± 9.20 (n=8) P<0.001
Ulnar Proximal (Elbow) 3.12 ± 1.35 (n=7) 10.39 ± 7.79 (n=7) P=0.24 8.17 ± 2.66 (n=7) 7.00 ± 1.83 (n=7) P=0.54 4.33 ± 2.37 (n=7) 11.76 ± 8.86 (n=7) P=0.26
Distal (Carpus) 4.3 7± 4.01 (n=9) 17.00 ± 14.80 (n=8) P=0.01 6.14 ± 2.02 (n=9) 5.75 ± 2.14 (n=8) P=0.91 5.01 ± 5.71 (n=9) 17.36 ± 15.26 (n=8) P<0.05

LPN – late-onset peripheral neuropathy; CMAP - compound muscle action potential